Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Juno Therapeutics
Juno Therapeutics
Activities:
Research & Development
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Media
Celgene set to become leader in CAR-T space
According to GlobalData, a data and analytics company, Celgene’s acquisition of Juno Therapeutics puts the company in a good position to be a frontrunner in the chimeric antigen receptor-T cell space
Research & Development
Juno Therapeutics and WuXi AppTec announce new company to develop novel cell-based cancer immunotherapies in China
JW Biotechnology will Leverage Juno's immuno-oncology expertise and assets and WuXi AppTec's R&D and manufacturing platform
You need to be a subscriber to read this article.
Click here
to find out more.
Research & Development
Homing in on cancer targets
Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach
Finance
Juno Therapeutics acquires German biotech Stage Cell Therapeutics for US$81m
Gaining access to transformative cell selection and activation capabilities
Research & Development
US cancer research centres launch biotech start-up
Juno Therapeutics will have US$120m initial investment and develop cancer immunotherapy products
Subscribe now